Loading…
Gufic Biosciences (GUFICBIO)₹474.35+8.72%Pharmaceuticals
Gufic Biosciences is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 64.8 against a peer median of 42.6, and ROCE of 12.0% against a peer median of 12.5%, and latest-quarter sales growth of 16.6% against a peer median of 18.6%. By market cap it is #6 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Morepen Laboratories | 5,433 | 29.2 | 8.0 | 5.3 | 0.17 | 0.2 | 1,808 | 96 | 80.9 | 117.0 | vs GUFICBIO |
| Senores Pharmaceuticals | 5,417 | 40.6 | 15.0 | 13.5 | 0.37 | 0.0 | 632 | 122 | 18.6 | 23.4 | vs GUFICBIO |
| Orchid Pharma | 5,291 | 421.0 | 2.0 | 1.3 | 0.28 | 0.0 | 1,229 | 10 | 15.5 | — | vs GUFICBIO |
| Supriya Lifescience | 5,082 | 24.3 | 25.1 | 19.1 | 0.00 | 0.2 | 826 | 209 | 50.7 | 48.1 | vs GUFICBIO |
| SMS Pharmaceuticals | 4,809 | 46.8 | 13.0 | 14.2 | 0.46 | 0.1 | 886 | 102 | 5.6 | 4.9 | vs GUFICBIO |
| Gufic Biosciences | 4,760 | 64.8 | 12.0 | 10.2 | 0.61 | 0.0 | 948 | 64 | 16.6 | 69.1 | — |
| Aarti Drugs | 4,563 | 24.0 | 12.1 | 13.4 | 0.37 | 0.4 | 2,564 | 194 | 18.9 | −7.5 | vs GUFICBIO |
| Zota Health Care | 4,410 | — | −8.0 | −15.1 | 0.39 | 0.1 | 539 | −74 | 54.2 | — | vs GUFICBIO |
| Evonile Pharma | 4,343 | 44.5 | 16.0 | 11.7 | 0.00 | 0.0 | 353 | 93 | 18.1 | 14.3 | vs GUFICBIO |
| RPG Life Sciences | 4,283 | 39.1 | 26.0 | 19.3 | 0.03 | 0.9 | 708 | 115 | 16.4 | −24.3 | vs GUFICBIO |
| Gujarat Themis Biosyn | 4,138 | 88.5 | — | — | — | 0.2 | 165 | 47 | 22.3 | 22.5 | vs GUFICBIO |
| Peer median | 4,760 | 42.6 | 12.5 | 12.5 | 0.33 | 0.1 | 826 | 96 | 18.6 | 22.5 |
Listed companies closest to Gufic Biosciences in Pharmaceuticals include Morepen Laboratories, Senores Pharmaceuticals, Orchid Pharma, Supriya Lifescience, SMS Pharmaceuticals, Aarti Drugs, Zota Health Care, Evonile Pharma.
Morepen Laboratories, with a market cap of ₹5,433 Cr.
Gufic Biosciences trades at a P/E of 64.8; the median of its peer set is 42.6. A P/E above or below the median is a description, not a judgement on value.
Gufic Biosciences' return on capital employed is 12.0%, below the peer median of 12.5%.